{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:56:28Z","timestamp":1791939388200,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011882","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000}}],"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004713"],"award-info":[{"award-number":["INV-004713"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Lymphatic filariasis (LF) is a neglected tropical disease (NTD) targeted by the World Health Organization for elimination as a public health problem (EPHP). Since 2000, more than 9 billion treatments of antifilarial medicines have been distributed through mass drug administration (MDA) programmes in 72 endemic countries and 17 countries have reached EPHP. Yet in 2021, nearly 900 million people still required MDA with combinations of albendazole, diethylcarbamazine and\/or ivermectin. Despite the reliance on these drugs, there remain gaps in understanding of variation in responses to treatment. As demonstrated for other infectious diseases, some urgent questions could be addressed by conducting individual participant data (IPD) meta-analyses. Here, we present the results of a systematic literature review to estimate the abundance of IPD on pre- and post-intervention indicators of infection and\/or morbidity and assess the feasibility of building a global data repository.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methodology<\/jats:title>\n<jats:p>We searched literature published between 1<jats:sup>st<\/jats:sup> January 2000 and 5<jats:sup>th<\/jats:sup> May 2023 in 15 databases to identify prospective studies assessing LF treatment and\/or morbidity management and disease prevention (MMDP) approaches. We considered only studies where individual participants were diagnosed with LF infection or disease and were followed up on at least one occasion after receiving an intervention\/treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Principal findings<\/jats:title>\n<jats:p>We identified 138 eligible studies from 23 countries, having followed up an estimated 29,842 participants after intervention. We estimate 14,800 (49.6%) IPD on pre- and post-intervention infection indicators including microfilaraemia, circulating filarial antigen and\/or ultrasound indicators measured before and after intervention using 8 drugs administered in various combinations. We identified 33 studies on MMDP, estimating 6,102 (20.4%) IPD on pre- and post-intervention clinical morbidity indicators only. A further 8,940 IPD cover a mixture of infection and morbidity outcomes measured with other diagnostics, from participants followed for adverse event outcomes only or recruited after initial intervention.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The LF treatment study landscape is heterogeneous, but the abundance of studies and related IPD suggest that establishing a global data repository to facilitate IPD meta-analyses would be feasible and useful to address unresolved questions on variation in treatment outcomes across geographies, demographics and in underrepresented groups. New studies using more standardized approaches should be initiated to address the scarcity and inconsistency of data on morbidity management.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0011882","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T18:28:45Z","timestamp":1705429725000},"page":"e0011882","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["The lymphatic filariasis treatment study landscape: A systematic review of study characteristics and the case for an individual participant data platform"],"prefix":"10.1371","volume":"18","author":[{"given":"Luzia T.","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashroor Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sauman","family":"Singh-Phulgenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyapal Dinesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumar","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Harriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Rahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Brack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-5365","authenticated-orcid":true,"given":"Martin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adinarayanan","family":"Srividya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"pntd.0011882.ref001","unstructured":"World Health Organization, 2021. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030. https:\/\/www.who.int\/publications\/i\/item\/9789240010352."},{"key":"pntd.0011882.ref002","first-page":"513","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2021","volume":"41","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"pntd.0011882.ref003","unstructured":"World Health Organization, 2023. Lymphatic Filariasis\u2013Key facts. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lymphatic-filariasis."},{"key":"pntd.0011882.ref004","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"pntd.0011882.ref005","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"key":"pntd.0011882.ref006","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study","volume":"16","author":"DOLF IDA Safety Study Group","year":"2019","journal-title":"PLoS Med"},{"key":"pntd.0011882.ref007","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in C\u00f4te d\u2019Ivoire: An Open-label Randomized Controlled Trial","volume":"71","author":"CM Bjerum","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pntd.0011882.ref008","doi-asserted-by":"crossref","first-page":"e0009069","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"P Jambulingam","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref009","unstructured":"World Health Organization, 2017. Guideline: Alternative Mass Drug Administration Regimens to eliminate Lymphatic filariasis. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/259381\/9789241550161-eng.pdf;jsessionid=D8C953E51E73ABDA076DA21C90F5DCDE?sequence=1."},{"key":"pntd.0011882.ref010","unstructured":"World Health Organization, 2023. Lymphatic filariasis: reporting continued progress towards elimination as a public health problem. https:\/\/www.who.int\/news\/item\/29-10-2020-lymphatic-filariasis-reporting-continued-progress-towards-elimination-as-a-public-health-problem."},{"key":"pntd.0011882.ref011","unstructured":"World Health Organization Global Programme to Eliminate Lymphatic Filariasis, 2013. Lymphatic filariasis: managing morbidity and preventing disability. https:\/\/www.who.int\/publications\/i\/item\/9789241505291."},{"key":"pntd.0011882.ref012","doi-asserted-by":"crossref","first-page":"e0004171","DOI":"10.1371\/journal.pntd.0004171","article-title":"The effect of hygiene-based lymphedema management in lymphatic filariasis-endemic areas: a systematic review and meta-analysis","volume":"9","author":"ME Stocks","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref013","first-page":"29","article-title":"Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned","volume":"106","author":"B Tripathi","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011882.ref014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pntd.0011882.ref015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"MA Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011882.ref016","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/cid\/ciab202","article-title":"Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial","volume":"73","author":"M Hardy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pntd.0011882.ref017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/tropicalmed6020044","article-title":"Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa","volume":"6","author":"PM Graves","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"9","key":"pntd.0011882.ref018","first-page":"1151","article-title":"Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration","volume":"63","author":"T Crellen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pntd.0011882.ref019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13071-016-1312-0","article-title":"New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel","volume":"9","author":"M Walker","year":"2016","journal-title":"Parasit Vectors"},{"key":"pntd.0011882.ref020","doi-asserted-by":"crossref","first-page":"e0009888","DOI":"10.1371\/journal.pntd.0009888","article-title":"Individual responses to a single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an area with high drug pressure","volume":"15","author":"M Walker","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref021","volume-title":"Sharing Clinical Research Data: Workshop Summary","author":"Institute of Medicine","year":"2013"},{"key":"pntd.0011882.ref022","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMp1607282","article-title":"Strengthening Research through Data Sharing","volume":"375","author":"E. Warren","year":"2016","journal-title":"N Engl J Med"},{"key":"pntd.0011882.ref023","doi-asserted-by":"crossref","first-page":"k400","DOI":"10.1136\/bmj.k400","article-title":"Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine","volume":"360","author":"F Naudet","year":"2018","journal-title":"BMJ"},{"key":"pntd.0011882.ref024","doi-asserted-by":"crossref","first-page":"e2215209","DOI":"10.1001\/jamanetworkopen.2022.15209","article-title":"Data Sharing and Reanalyses Among Randomized Clinical Trials Published in Surgical Journals Before and After Adoption of a Data Availability and Reproducibility Policy","volume":"5","author":"D Bergeat","year":"2022","journal-title":"JAMA Netw Open"},{"key":"pntd.0011882.ref025","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMp1605148","article-title":"Avoiding Data Dumpsters\u2014Toward Equitable and Useful Data Sharing","volume":"374","author":"L Merson","year":"2016","journal-title":"N Engl J Med"},{"key":"pntd.0011882.ref026","doi-asserted-by":"crossref","first-page":"i5295","DOI":"10.1136\/bmj.i5295","article-title":"Beyond open data: realising the health benefits of sharing data","volume":"355","author":"E Pisani","year":"2016","journal-title":"BMJ"},{"key":"pntd.0011882.ref027","doi-asserted-by":"crossref","first-page":"e0009697","DOI":"10.1371\/journal.pntd.0009697","article-title":"The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform","volume":"15","author":"BJ Maguire","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref028","article-title":"Infectious Diseases Data Observatory (IDDO) Visceral Leishmaniasis Library of Clinical Therapeutic Studies: A Protocol for a Living Systematic Review of Clinical Studies","author":"S Singh-Phulgenda","year":"2021","journal-title":"Research Square"},{"key":"pntd.0011882.ref029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/wellcomeopenres.17468.1","article-title":"Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data","volume":"7","author":"M Walker","year":"2022","journal-title":"Wellcome Open Res"},{"key":"pntd.0011882.ref030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41597-022-01534-9","article-title":"ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19","volume":"9","author":"ISARIC Clinical Characterization Group","year":"2022","journal-title":"Sci Data"},{"key":"pntd.0011882.ref031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cub.2013.11.014","article-title":"The availability of research data declines rapidly with article age","volume":"24","author":"TH Vines","year":"2014","journal-title":"Curr Biol"},{"key":"pntd.0011882.ref032","doi-asserted-by":"crossref","first-page":"e0004784","DOI":"10.1371\/journal.pntd.0004784","article-title":"The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD)","volume":"10","author":"AM Jul\u00e9","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref033","doi-asserted-by":"crossref","first-page":"e0006053","DOI":"10.1371\/journal.pntd.0006053","article-title":"Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiases and the case for data-sharing","volume":"11","author":"JB Halder","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref034","doi-asserted-by":"crossref","first-page":"e0005781","DOI":"10.1371\/journal.pntd.0005781","article-title":"Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform","volume":"11","author":"JT Bush","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref035","unstructured":"Falconer, J. Removing duplicates from an EndNote library. http:\/\/blogs.lshtm.ac.uk\/library\/2018\/12\/07\/removing-duplicates-from-an-endnote-library\/ (Accessed August 19, 2021)."},{"key":"pntd.0011882.ref036","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jclinepi.2020.01.008","article-title":"A full systematic review was completed in 2 weeks using automation tools: a case study","volume":"121","author":"J Clark","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"pntd.0011882.ref037","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"REDCap Consortium","year":"2019","journal-title":"J Biomed Inform"},{"key":"pntd.0011882.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v084.i06","article-title":"tmap: Thematic Maps in R","volume":"84","author":"M. Tennekes","year":"2018","journal-title":"J Stat Soft"},{"key":"pntd.0011882.ref039","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. https:\/\/www.R-project.org."},{"key":"pntd.0011882.ref040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/000349804225003172","article-title":"A 26-year follow-up of bancroftian filariasis in two communities in north-eastern Tanzania","volume":"98","author":"DW Meyrowitsch","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0011882.ref041","doi-asserted-by":"crossref","first-page":"e1940","DOI":"10.1371\/journal.pntd.0001940","article-title":"Antibody to the filarial antigen Wb123 reflects reduced transmission and decreased exposure in children born following single mass drug administration (MDA)","volume":"6","author":"C Steel","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref042","doi-asserted-by":"crossref","first-page":"e1919325","DOI":"10.1001\/jamanetworkopen.2019.19325","article-title":"Limitations of meta-analyses of studies with high heterogeneity","volume":"3","author":"PB Imrey","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pntd.0011882.ref043","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmjebm-2022-111931","article-title":"Using individual participant data to improve network meta-analysis projects","volume":"28","author":"RD Riley","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"pntd.0011882.ref044","doi-asserted-by":"crossref","first-page":"e01015","DOI":"10.1136\/bmjgh-2022-010157","article-title":"What constitutes equitable data sharing in global health research? A scoping review of the literature on low-income and middle-income country stakeholders\u2019 perspectives","volume":"8","author":"N Evertsz","year":"2023","journal-title":"BMJ Global Health"},{"key":"pntd.0011882.ref045","doi-asserted-by":"crossref","first-page":"e83433","DOI":"10.7554\/eLife.83433","article-title":"The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis","volume":"11","author":"JA Watson","year":"2022","journal-title":"Elife"},{"key":"pntd.0011882.ref046","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(22)01881-5","article-title":"Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis","volume":"401","author":"M Saito","year":"2022","journal-title":"Lancet"},{"key":"pntd.0011882.ref047","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12916-022-02504-z","article-title":"Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data","volume":"20","author":"K Stepniewska","year":"2022","journal-title":"BMC Med"},{"key":"pntd.0011882.ref048","doi-asserted-by":"crossref","first-page":"e0009144","DOI":"10.1371\/journal.pntd.0009144","article-title":"A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?","volume":"15","author":"P Jittamala","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref049","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/irv.13039","article-title":"Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients","volume":"16","author":"ISARIC Clinical Characterisation Group","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"pntd.0011882.ref050","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/inthealth\/ihaa058","article-title":"African regional progress and status of the programme to eliminate lymphatic filariasis: 2000\u20132020","author":"K Deribe","year":"2020","journal-title":"Int Health"},{"key":"pntd.0011882.ref051","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis","volume":"8","author":"MG Bas\u00e1\u00f1ez","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011882.ref052","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/cid\/cix616","article-title":"Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness","volume":"65","author":"M Walker","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pntd.0011882.ref053","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-Dose Triple-Drug Therapy for Wuchereria bancrofti\u20145-Year Follow-up","volume":"382","author":"CL King","year":"2020","journal-title":"N Engl J Med"},{"key":"pntd.0011882.ref054","volume-title":"Sharing Research Data to Improve Public Health in Africa: A Workshop Summary","author":"Committee on Population; Division of Behavioral and Social Sciences and Education","year":"2015"},{"key":"pntd.0011882.ref055","doi-asserted-by":"crossref","first-page":"e0008298","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study","volume":"14","author":"CL Dubray","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref056","doi-asserted-by":"crossref","first-page":"e0010096","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial","volume":"16","author":"L Tavul","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref057","doi-asserted-by":"crossref","first-page":"e0009294","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"T Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref058","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"P Milton","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"pntd.0011882.ref059","doi-asserted-by":"crossref","first-page":"e0006453","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref060","doi-asserted-by":"crossref","first-page":"e0007697","DOI":"10.1371\/journal.pntd.0007697","article-title":"Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis","volume":"13","author":"BJ Andersen","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref061","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4269\/ajtmh.19-0532","article-title":"Frequency and clinical significance of localized adverse events following mass drug administration for lymphatic filariasis in an endemic area in South India","volume":"102","author":"VS Kuttiatt","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011882.ref062","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1469-0691.2011.03586.x","article-title":"Filariasis in Africa\u2014treatment challenges and prospects","volume":"17","author":"A Hoerauf","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"pntd.0011882.ref063","doi-asserted-by":"crossref","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"PU Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011882.ref064","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1705026","article-title":"A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas","volume":"377","author":"J Kamgno","year":"2017","journal-title":"N Engl J Med"},{"key":"pntd.0011882.ref065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4103\/ijcm.IJCM_12_21","article-title":"Assessment of the impact of morbidity management and disability prevention for lymphatic filariasis on the disease burden in Villupuram District of Tamil Nadu, India","volume":"46","author":"L Mathiarasan","year":"2021","journal-title":"Indian J Community Med"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011882","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T18:39:53Z","timestamp":1706294393000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011882"}},"subtitle":[],"editor":[{"given":"Sabine","family":"Specht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011882","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011882","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}